Table S1 Antibodies used in this study.

Target protein	Supplier	Catalog number
CMTM8	Proteintech	15039-1-AP
LPA1	Thermo Fisher Scientific	CF503737
Non-phospho β-catenin	Cell Signaling Technology	#8814
β-catenin	Cell Signaling Technology	#8480
Phospho-GSK3β	Abcam	ab131097
GSK3β	Abcam	ab93926
GAPDH	Cell Signaling Technology	#2118

Table S2 siRNA sequences and PCR primers.

siRNA target sites	
siLPA1#1	5′-GGCTGCTGCAGACTTCTTT-3′
siLPA1#2	5′-TCTCTATGCTCACATCTTT-3′
si-β-catenin#1	5′-CCAGACACGCTATCATGCG-3′
si-β-catenin#2	5′-TTGGATTGATTCGAAATCT-3′
PCR primers	
LPA1 forward	5′-GCCACAGAATGGAACACAGT-3′
LPA1 reverse	5′-GCAGCCAGATTAGCCATTAG-3′
CMTM8 forward	5′-CTTCCTGGTCACCATCTGCT-3′
CMTM8 reverse	5′-CAATTCTCTGGGAATATACA-3′
β-catenin forward	5′-AAAGCGGCTGTTAGTCACTGG-3′
β-catenin reverse	5′-CGAGTCATTGCATACTGTCCAT-3′
GAPDH forward	5′-ACCACAGTCCATGCCATCAC-3′
GAPDH reverse	5′-GTCAGGTCCACCACTGACACG-3′



Figure S1 Effect of LPA treatment on the expression of CMTM8 mRNA. n.s. indicates no significance relative to vehicle-treated cells.



Figure S2 Effect of CMTM8 on pancreatic cancer growth. (A) Analysis of cell proliferation by MTT assay in CMTM8-overexpressing and control cells. (B) Colony formation assay. The number of colonies was counted after culturing for 10-14 days. n.s. indicates no significance. Data are expressed as mean ± SD (n = 3).

Table S3 Correlation between CMTM8 expression and clinicopathological features of pancreatic cancer patients (n = 64)

Variable	n	CMTM8		P
		Low expression (n = 30)	High expression (n = 34)	
Age, years				0.7900
<60	31	14	17	
≥60	33	16	17	
Gender				0.3652
Male	40	17	23	
Female	24	13	11	
TNM stage				0.5487
I	19	10	9	
II-III	45	20	25	
Tumor size, cm				0.3855
<5	48	21	27	
≥5	16	9	7	
Lymph node metastasis				0.4955
Negative	27	14	13	
Positive	37	16	21	



Figure S3 Silencing of CMTM8 had no significant impact on the migration and invasion of pancreatic cancer cells induced by TGF-β1. (A and B) CFPAC-1 and PANC-1 cells were transfected with control or CMTM8 shRNA before exposure to TGF-β1, and then subjected to (A) wound-healing and (B) Transwell invasion assays. $^{*}P < 0.05$. n.s. indicates no significance. Data are expressed as mean ± SD (n = 3).



Figure S4 LPA1 activity is required for CMTM8 protein expression and function. (A) Representative Western blots showing the reduction of CMTM8 protein in PANC-1 cells treated with ki16425 (10 μM) for 30 min. (B) In vitro wound-healing and (C) Transwell invasion assays were performed to assess the migration and invasion capacity, respectively, of pancreatic cancer cells transfected as in (A). $^{*}P < 0.05$ *vs.* the vehicle group. Data are expressed as mean ± SD (n = 3). (D) Western blot analysis of indicated proteins in LPA1-overexpressing pancreatic cancer cells.